[Solacy and non-specific chronic laryngitis].
Adult subjects, without age or sex distinction, presenting a non-specific chronic laryngitis were treated with SOLACY. The posology of SOLACY administered was: 2 capsules in the morning and 2 at night for four months in a row. The subjects were seen at least twice: one consultation before the treatment and one after the 4 months of treatment. These consultations included an interview and fibroscopic test of the laryngeal mucosa (photographs were taken). The subjects were also requested to quantify the overall discomfort experienced. Ten subjects were recruited for this study. Dysphonia was significantly lower after the 4-month treatment as was the self-evaluation of the overall discomfort brought on by the different symptoms. In addition, it can be noted that SOLACY lessened coughing and laryngeal discomfort in most of the patients treated and it improved the fibroscopic test results, especially concerning the congestive aspect of the laryngeal mucosa, whether limited to vocal chords or spread throughout the entire vestibule. The treatment was tolerated perfectly well. In conclusion, SOLACY, administered in adults presenting non-specific chronic laryngitis improves the state of the laryngeal mucosa and its main symptoms (dysphonia, coughing, laryngeal discomfort).
Berezin
A
A
D000328:Adult; D002908:Chronic Disease; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007827:Laryngitis / Q000188:drug therapy*; D008297:Male; D013455:Sulfur / Q000627:therapeutic use*; D014801:Vitamin A / Q000627:therapeutic use*
D004338:Drug Combinations; D014801:Vitamin A; D013455:Sulfur
Solacy et laryngite chronique non spécifique.